PMID- 34034099
OWN - NLM
STAT- MEDLINE
DCOM- 20220411
LR  - 20220411
IS  - 1873-7862 (Electronic)
IS  - 0924-977X (Linking)
VI  - 51
DP  - 2021 Oct
TI  - Comparative outcomes in electroconvulsive therapy (ECT): A naturalistic 
      comparison between outcomes in psychosis, mania, depression, psychotic depression 
      and catatonia.
PG  - 43-54
LID - S0924-977X(21)00221-2 [pii]
LID - 10.1016/j.euroneuro.2021.04.023 [doi]
AB  - Electroconvulsive Therapy's (ECT) use and place in treatment guidelines varies 
      worldwide with a primary indication of depression in Western countries and acute 
      psychosis in Asian countries. There is sparse evidence about the relative 
      effectiveness of ECT among different indications that may account for this 
      discrepancy. We aimed to compare the clinical global impression of disease 
      severity, cognitive change, subjective quality of life (QoL) and global 
      functioning after ECT given for treatment of the indications of acute psychosis, 
      mania, depression, psychotic depression and catatonia. We conducted a 
      retrospective naturalistic cohort study with post-hoc analyses of patients' ECT 
      registry data from 2017 to 2019. 691 patients were assessed before and after 6 
      sessions of ECT treatment, using the Clinical Global Impression-Improvement and 
      Severity (CGI-I and CGI-S) scale, Montreal Cognitive Assessment (MoCA), Quality 
      of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF), EQ-5D 
      utility score and Global Assessment of Functioning (GAF) scale. The pre-ECT vs 
      post-ECT clinical assessment change scores were compared within and across the 
      five indications. For each indication, there were large improvements in clinical 
      global impression of disease severity, QoL and global functioning. There were no 
      significant changes in MoCA score for most indications except for an improvement 
      in patients with schizophrenia. ECT is a rapidly acting and effective acute 
      treatment across several severe mental illnesses with large improvements in 
      symptoms, QoL and global functioning.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - Tor, Phern Chern
AU  - Tor PC
AD  - Department of Mood and Anxiety, Institute of Mental Health, Singapore 539747; 
      Neurostimulation Service, Institute of Mental Health, Singapore 539747; Duke-NUS 
      Graduate Medical School, Singapore 169857. Electronic address: 
      Phern_Chern_Tor@imh.com.sg.
FAU - Tan, Xiao Wei
AU  - Tan XW
AD  - Department of Mood and Anxiety, Institute of Mental Health, Singapore 539747.
FAU - Martin, Donel
AU  - Martin D
AD  - School of Psychiatry, University of New South Wales, Randwick, NSW, 2031, 
      Australia; Black Dog Institute, Hospital Road, Randwick, NSW, 2031, Australia.
FAU - Loo, Colleen
AU  - Loo C
AD  - School of Psychiatry, University of New South Wales, Randwick, NSW, 2031, 
      Australia; Black Dog Institute, Hospital Road, Randwick, NSW, 2031, Australia; 
      The Wesley Hospital, 7 Blake St, Kogarah, NSW, 2217, Australia; St. George 
      Hospital, Gray St, Kogarah, NSW, 2217, Australia; Northside Group St Leonards 
      Clinic, 2 Frederick St, St Leonards, NSW, 2065, Australia.
LA  - eng
PT  - Journal Article
DEP - 20210523
PL  - Netherlands
TA  - Eur Neuropsychopharmacol
JT  - European neuropsychopharmacology : the journal of the European College of 
      Neuropsychopharmacology
JID - 9111390
SB  - IM
MH  - *Catatonia/therapy
MH  - Cohort Studies
MH  - Depression
MH  - *Electroconvulsive Therapy
MH  - Humans
MH  - Mania
MH  - *Psychotic Disorders/therapy
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bipolar disorder
OT  - Cognitive function
OT  - Depression
OT  - Electroconvulsive therapy
OT  - Quality of life
OT  - Schizophrenia
COIS- Conflict of Interest Authors declare no conflict of interest
EDAT- 2021/05/26 06:00
MHDA- 2022/04/12 06:00
CRDT- 2021/05/25 20:21
PHST- 2021/03/19 00:00 [received]
PHST- 2021/04/27 00:00 [revised]
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/05/26 06:00 [pubmed]
PHST- 2022/04/12 06:00 [medline]
PHST- 2021/05/25 20:21 [entrez]
AID - S0924-977X(21)00221-2 [pii]
AID - 10.1016/j.euroneuro.2021.04.023 [doi]
PST - ppublish
SO  - Eur Neuropsychopharmacol. 2021 Oct;51:43-54. doi: 
      10.1016/j.euroneuro.2021.04.023. Epub 2021 May 23.